ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Genelux Corporation

Genelux Corporation (GNLX)

2.20
-0.08
( -3.51% )
Updated: 12:38:18

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.20
Bid
2.20
Ask
2.21
Volume
85,805
2.16 Day's Range 2.3568
2.15 52 Week Range 40.98
Market Cap
Previous Close
2.28
Open
2.31
Last Trade
78
@
2.2
Last Trade Time
12:38:17
Financial Volume
$ 196,795
VWAP
2.2935
Average Volume (3m)
234,748
Shares Outstanding
26,996,740
Dividend Yield
-
PE Ratio
-2.09
Earnings Per Share (EPS)
-1.05
Revenue
170k
Net Profit
-28.3M

About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Genelux Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GNLX. The last closing price for Genelux was $2.28. Over the last year, Genelux shares have traded in a share price range of $ 2.15 to $ 40.98.

Genelux currently has 26,996,740 shares outstanding. The market capitalization of Genelux is $59.12 million. Genelux has a price to earnings ratio (PE ratio) of -2.09.

GNLX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.15-6.38297872342.352.482.151550092.34178049CS
4-1.29-36.96275071633.493.52.154025292.6100164CS
12-4.3-66.15384615386.56.52.152347483.31166428CS
26-11.3-83.703703703713.516.62.151715365.48394691CS
52-34.96-94.079655543637.1640.982.1516789813.24946408CS
156-3.8-63.3333333333640.982.1514649614.61252257CS
260-3.8-63.3333333333640.982.1514649614.61252257CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.8037
(167.01%)
273.97M
SHCRSharecare Inc
$ 1.365
(76.27%)
32.68M
NXLNexalin Technologies Inc
$ 1.84
(67.27%)
39.9M
SPECSpectaire Holdings Inc
$ 0.537683
(58.14%)
58.64M
MINMMinim Inc
$ 3.885
(35.84%)
41.31M
KAVLKaival Brands Innovations Group Inc
$ 1.475
(-48.61%)
3.24M
PBMPsyence Biomedical Ltd
$ 0.3931
(-34.48%)
2.17M
JSPRWJasper Therapeutics Inc
$ 0.1618
(-26.45%)
6.25k
RELIReliance Global Group Inc
$ 0.4631
(-23.32%)
7.23M
SMXSMX Security Matters Public Company
$ 0.129
(-19.78%)
10.15M
NVDANVIDIA Corporation
$ 129.3399
(-1.10%)
278.08M
AREBAmerican Rebel Holdings Inc
$ 0.8062
(167.84%)
273.98M
CRKNCrown Electrokinetics Corporation
$ 0.0414
(-17.20%)
131.44M
ASTIAscent Solar Technologies Inc
$ 0.1146
(6.21%)
110.61M
NKLANikola Corporation
$ 0.3684
(11.77%)
110.52M

Your Recent History

Delayed Upgrade Clock